Payment overview · 2025
General Payments
$364.92
18 reported records · 9 companies
Healthcare provider profile · identity verified
Michael A Montoya, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALBUQUERQUE, NM · NPI 1215046545
Verified facts
What the public records show
CMS Open Payments records show Michael A Montoya, MD received $364.92 in general payments during 2025 across 18 reported records.
Exact Sciences Corporation accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $130.43 | 35.7% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.22 | 14.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.22 | 14.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.79 | 8.4% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.81 | 7.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.81 | 6.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.49 | 4.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.48 | 4.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.67 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $364.92 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.68 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $54.75 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $34.97 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.79 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 129 |
| Losartan Potassium | Losartan Potassium | 317 | 104 |
| Oxycodone Hcl | Oxycodone Hcl | 285 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 254 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 246 | 81 |
| Lisinopril | Lisinopril | 225 | 69 |
| Metformin Hcl | Metformin Hcl | 213 | 70 |
| Ibuprofen | Ibuprofen | 202 | 46 |
| Gabapentin | Gabapentin | 181 | 53 |
| Tramadol Hcl | Tramadol Hcl | 177 | 30 |
| Alprazolam | Alprazolam | 157 | 33 |
| Clonazepam | Clonazepam | 157 | 21 |
| Baclofen | Baclofen | 142 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 141 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 50 |
| Omeprazole | Omeprazole | 127 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 118 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 34 |
| Famotidine | Famotidine | 101 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 16 |
| Finasteride | Finasteride | 99 | 29 |
| Glimepiride | Glimepiride | 95 | 32 |
| Allopurinol | Allopurinol | 84 | 28 |
| Meloxicam | Meloxicam | 84 | 26 |
| Trazodone Hcl | Trazodone Hcl | 84 | 15 |
| Simvastatin | Simvastatin | 76 | 24 |
| Carvedilol | Carvedilol | 75 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 22 |
| Lorazepam | Lorazepam | 72 | 15 |
| Buspirone Hcl | Buspirone Hcl | 69 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 65 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 22 |
| Trulicity | Dulaglutide | 62 | 11 |
| Diazepam | Diazepam | 61 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 23 |
| Lovastatin | Lovastatin | 58 | 17 |
| Sertraline Hcl | Sertraline Hcl | 58 | 21 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Azithromycin | Azithromycin | 56 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 55 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 17 |
| Acyclovir | Acyclovir | 53 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 14 |
| Montelukast Sodium | Montelukast Sodium | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 15 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 22 |
| Spironolactone | Spironolactone | 40 | 14 |
| Temazepam | Temazepam | 39 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 11 |
| Ozempic | Semaglutide | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | 11 |
| Estradiol | Estradiol | 35 | 13 |
| Amoxicillin | Amoxicillin | 34 | 29 |
| Jardiance | Empagliflozin | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 14 |
| Eliquis | Apixaban | 33 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Nateglinide | Nateglinide | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 12 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 14 |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 23 | suppressed |
| Prednisone | Prednisone | 23 | 17 |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Furosemide | Furosemide | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $364.92 · 18 records | Exact Sciences Corporation | ABRYSVO, BREZTRI, COMIRNATY, Cologuard Collection Kit, FARXIGA, Intracept, JARDIANCE, NURTEC ODT, Ozempic, PREVNAR 20, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, ZAVZPRET, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error